Oesophageal cancer located above the level of the tracheal bifurcation is frequently complicated by its spread into the airways and by the simultaneous occurrence of malignant bronchial tumours. Although bronchoscopy is an essential procedure in identifying malignant tumoral invasion of the airways and detection of primary airway tumours in patients with suprabifurcal oesophageal cancer, its role in patients with infrabifurcal oesophageal cancer is not clear. This study aimed to assess the value of fibreoptic bronchoscopy in the preoperative staging of oesophageal cancer located below the level of the tracheal bifurcation. In a prospective protocol, bronchoscopic findings were correlated with the results of other staging procedures, operative results and survival in 51 patients with oesophageal cancer located below the level of the tracheal bifurcation. One unsuspected primary bronchial cancer in a patient with squamous cell oesophageal cancer and one case of lower lobe invasion of an oesophageal adenocarcinoma were found. By excluding from surgery these two patients in whom curative resection was not possible bronchoscopy was the sole decisive staging investigation in 6.5% of potentially operable and 3.9% of all patients. Suspect macroscopic abnormalities were shown in 15.7% of the patients at bronchoscopy. Taking bronchoscopic biopsy as the gold standard the positive predictive value for all macroscopic abnormalities was only 25% (95% confidence interval (CI) 3.2-65.1%). The overall accuracy of bronchoscopy with biopsy and brush and washing cytology in proving or excluding airway invasion in otherwise potentially operable patients was 100% (95% CI 89.4-100%). Bronchoscopy is useful in the preoperative staging of oesophageal carcinoma located below the level of the tracheal bifurcation, particularly if the oesophageal cancer is of the squamous cell type.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1034/j.1399-3003.2000.16a24.x | DOI Listing |
Esophagus
January 2025
Department of Medical Oncology, National Taiwan University Cancer Center, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Esophageal squamous cell carcinoma (ESCC) is a prevalent and highly lethal malignancy in Asia. Recent advancements in immune checkpoint inhibitors (ICIs) have markedly transformed the systemic therapy landscape for ESCC. Anti-PD-1-based combination with chemotherapy or with ipilimumab, an anti-CTLA-4 antibody, have been established as the new standard first-line treatments for patients with advanced ESCC.
View Article and Find Full Text PDFMol Biol Rep
January 2025
Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Background: The methyltransferase gene family is known for its diverse biological functions and critical role in tumorigenesis. This study aimed to identify these family genes in common gastrointestinal (GI) cancers using comprehensive methodologies.
Methods: Gene identification involved analysis of scientific literature and insights from The Cancer Genome Atlas (TCGA) database.
Oncologist
January 2025
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Whether preoperative chemoradiotherapy (CRT) or perioperative chemotherapy is superior for localized esophageal or gastro-esophageal junction (GEJ) cancers has been a topic of long-standing debate. For years, standard of care in the United States for localized esophageal or GEJ adenocarcinoma (EAC) has been physician's choice between the 2 strategies. More recently, adjuvant immunotherapy has also been introduced into the treatment approach for those who received neoadjuvant CRT.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Introduction: The prognostic impact of human leukocyte antigen-E (HLA-E) expression and the proportion of natural killer (NK) cells in esophageal squamous cell carcinoma (ESCC) was investigated.
Methods: This study retrospectively evaluated 397 ESCC patients across two centers. The cumulative incidence of recurrence (CIR) and the incidence of tumor-related death (CID) were analyzed in various groups.
Front Immunol
January 2025
Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
We reported the pseudoprogression in an elderly patient with advanced gastric cancer after chimeric antigen receptor (CAR)-T cell therapy. The hepatic metastases enlarged 1 month after CAR-T cell infusion and then shrunk the next month as seen through computed tomography scanning. Based on a comprehensive evaluation that includes imaging, pathology, serum tumor markers, and clinical symptoms, we arrived at a diagnosis of pseudoprogression after CAR-T cell therapy, which has not been reported in previous studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!